| 2nd Sep 2021 12:45 pm |
RNS |
Grant of Share Options, and Awards under LTIP |
| 31st Aug 2021 9:30 am |
RNS |
Total Voting Rights |
| 26th Aug 2021 7:00 am |
RNS |
Phase Ib/II Trial of Fruquintinib & Tislelizumab |
| 23rd Aug 2021 7:00 am |
RNS |
HUTCHMED Selected for Certain Hang Seng Indexes |
| 17th Aug 2021 9:30 am |
RNS |
ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION |
| 9th Aug 2021 7:00 am |
RNS |
HUTCHMED & Epizyme Announce TAZVERIK Collaboration |
| 30th Jul 2021 9:30 am |
RNS |
Total Voting Rights |
| 28th Jul 2021 12:00 pm |
RNS |
Interim Results and Business Updates |
| 28th Jul 2021 7:00 am |
RNS |
Phase II Trial of ORPATHYS Initiated |
| 23rd Jul 2021 12:01 pm |
RNS |
Stabilizing Actions & End of Stabilization Period |
| 16th Jul 2021 10:50 am |
RNS |
Holding(s) in Company |
| 16th Jul 2021 7:00 am |
RNS |
Surufatinib MAA Submitted and Validated by the EMA |
| 14th Jul 2021 9:35 am |
RNS |
Holding(s) in Company |
| 13th Jul 2021 7:00 am |
RNS |
First Commercial Sale of ORPATHYS® in China |
| 12th Jul 2021 2:35 pm |
RNS |
Full Exercise of the Over-allotment Option |
| 6th Jul 2021 9:30 am |
RNS |
HUTCHMED Initiates Phase I Trials of HMPL-295 |
| 2nd Jul 2021 11:15 am |
RNS |
Holding(s) in Company |
| 2nd Jul 2021 9:30 am |
RNS |
Notice of Results |
| 1st Jul 2021 11:00 am |
RNS |
US FDA Accepts NDA Filing for Surufatinib |
| 30th Jun 2021 10:02 am |
RNS |
Holdings in Company |
| 30th Jun 2021 10:01 am |
RNS |
Total Voting Rights |
| 30th Jun 2021 10:00 am |
RNS |
Closing of Global Offering and Hong Kong Listing |
| 29th Jun 2021 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 23rd Jun 2021 3:21 pm |
RNS |
HUTCHMED Announces Pricing of Global Offering |
| 22nd Jun 2021 6:22 pm |
RNS |
Savolitinib approved in China for lung cancer |
| 18th Jun 2021 4:05 pm |
RNS |
HUTCHMED Announces NMPA Approval of Surufatinib |
| 18th Jun 2021 7:01 am |
RNS |
HUTCHMED Launches Hong Kong IPO |
| 18th Jun 2021 7:00 am |
RNS |
Disclosure Update |
| 20th May 2021 7:00 am |
RNS |
Clinical Data to be Presented at ASCO21 |
| 17th May 2021 7:00 am |
RNS |
HUTCHMED to Host Company Update |
| 7th May 2021 12:00 pm |
RNS |
HUTCHMED to Attend Upcoming Investor Conferences |
| 4th May 2021 8:00 am |
RNS |
Change of Company Name |
| 4th May 2021 7:00 am |
RNS |
Surufatinib FDA Rolling NDA Submission Completed |
| 30th Apr 2021 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 30th Apr 2021 4:35 pm |
RNS |
Price Monitoring Extension |
| 29th Apr 2021 7:00 am |
RNS |
Phase II Registration Study of HMPL-689 Initiated |
| 28th Apr 2021 2:20 pm |
RNS |
Result of AGM |
| 23rd Apr 2021 7:00 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 14th Apr 2021 10:30 am |
RNS |
Notification of Dilution of Voting Rights |
| 8th Apr 2021 8:30 am |
RNS |
$100m Investment by Baring Private Equity Asia |
